119P Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence

In hormone receptor-positive, HER2-negative metastatic breast cancer (HR+ HER2- MBC), cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combination with endocrine treatment comprise the mainstay of treatment. This study aims to evaluate the clinical outcomes by treatment sequence between the two regimens. HR+ HER2- MBC patients treated with both CDK4/6 inhibitor and EVE from Jan 2014 to Nov 2020 were retrospectively...